/PSTX

PSTX Stock - Poseida Therapeutics, Inc.

Q: What is the analyst price target for PSTX?

Analyst price target information is not currently available for PSTX.

Q: What is PSTX's market cap?

Market capitalization information is not currently available for PSTX.

Healthcare|Biotechnology|NASDAQ

$9.50+0.00%

+$0.00 (+0.00%) • Jan 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+31.6%upside

Target: $12.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PSTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.54

52W High$9.67

52W Low$1.87

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$64.70M	$130.36M	$31,238	N/A	N/A
Gross Profit	$-92,069,000	$125.19M	$-4,520,762	$-2,586,000	$-1,193,000
Gross Margin	-142.3%	96.0%	-14472.0%	N/A	N/A
Operating Income	$-129,504,000	$-59,946,000	$-141,411	$-126,549	$-85,533,000
Net Income	$-123,430,000	$-64,002,000	$4.40M	$2.45M	$-92,639,000
Net Margin	-190.8%	-49.1%	14097.8%	N/A	N/A
EPS	$-1.37	$-0.89	$0.07	$0.04	$-2.33

Company Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$13

Average Target

↑ 31.6% Upside

Now

$10

Low

$13

Average

$15

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 2nd 2024	Piper Sandler	Downgrade	Neutral	$10
January 4th 2023	H.C. Wainwright	Initiation	Buy	$15

Earnings History & Surprises

PSTX

Beat Rate

61%

Last 18 quarters

Avg Surprise

+17.8%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$0.21

Q4 2024

EPS Surprise History

Q1 23

-183.0%

$-0.39vs$0.47

Q2 23

-12.5%

$-0.45vs$-0.40

Q3 23

+39.6%

$-0.32vs$-0.53

Q4 23

-20.7%

$-0.35vs$-0.29

Q1 24

+25.0%

$-0.27vs$-0.36

Q2 24

+41.9%

$-0.25vs$-0.43

Q3 24

+25.6%

$-0.32vs$-0.43

Q4 24

+151.2%

$0.21vs$-0.41

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 7, 2024	$-0.41	$0.21	+151.2%	✓ BEAT
Q3 2024	Aug 5, 2024	$-0.43	$-0.32	+25.6%	✓ BEAT
Q2 2024	May 14, 2024	$-0.43	$-0.25	+41.9%	✓ BEAT
Q1 2024	Mar 7, 2024	$-0.36	$-0.27	+25.0%	✓ BEAT
Q4 2023	Nov 9, 2023	$-0.29	$-0.35	-20.7%	✗ MISS
Q3 2023	Aug 8, 2023	$-0.53	$-0.32	+39.6%	✓ BEAT
Q2 2023	May 9, 2023	$-0.40	$-0.45	-12.5%	✗ MISS
Q1 2023	Mar 9, 2023	$0.47	$-0.39	-183.0%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.65	$0.92	+241.5%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.84	$-0.69	+17.9%	✓ BEAT
Q2 2022	May 12, 2022	$-0.58	$-0.93	-60.3%	✗ MISS
Q1 2022	Mar 10, 2022	$-0.35	$0.02	+105.7%	✓ BEAT
Q4 2021	Nov 9, 2021	$-0.75	$-0.68	+9.3%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.64	$-0.74	-15.6%	✗ MISS
Q2 2021	May 11, 2021	$-0.67	$-0.62	+7.5%	✓ BEAT
Q1 2021	Mar 11, 2021	$-0.69	$-0.58	+15.9%	✓ BEAT
Q4 2020	Nov 12, 2020	$-0.55	$-0.63	-14.5%	✗ MISS
Q3 2020	Aug 20, 2020	$-1.48	$-2.28	-54.1%	✗ MISS
Q3 2020	Jul 10, 2020	—	$-0.50	—	—
Q4 2019	Dec 31, 2019	—	$-0.59	—	—

Frequently Asked Questions about PSTX

What is PSTX's current stock price?

Poseida Therapeutics, Inc. (PSTX) is currently trading at $9.50 per share. The stock has moved +0.00% today.

What is the analyst price target for PSTX?

The average analyst price target for PSTX is $12.50, based on 1 analyst.

What sector is Poseida Therapeutics, Inc. in?

Poseida Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PSTX's market cap?

Poseida Therapeutics, Inc. has a market capitalization of $0.93 billion, making it a small-cap company.

Does PSTX pay dividends?

No, Poseida Therapeutics, Inc. does not currently pay a dividend to shareholders.